Podcasts about sbrt

Can high-precision radiation change how we treat metastatic prostate cancer? In this episode, I'm joined by Ronald C. Chen, MD, MPH—radiation oncologist, national guideline author (AUA/ASCO), and clinical-trial leader with 170+ publications—to unpack stereotactic body radiation therapy (SBRT) for disease that has spread to lymph nodes, bones, and beyond. We get practical about who benefits, where SBRT shines, and how to balance treatment intensity with quality of life.SBRT offers highly focused, short-course radiation that can control limited (“oligo-”) metastatic prostate cancer and delay systemic therapy for many men. Dr. Chen explains when to treat individual nodes/bone lesions versus comprehensive nodal fields, how anatomy determines dose/fraction choices (often 3–5 treatments), and why modern SBRT sometimes reduces the need for concurrent hormone therapy. We cover salvage options after prior radiation (brachytherapy seeds, HIFU, cryo, repeat SBRT, or salvage prostatectomy), the role and limits of PSMA PET, fracture risk and bone health (DEXA), and the evolving data—including the large NRG-GU013 trial—for higher-risk disease. Throughout, we emphasize shared decision-making, realistic expectations, and considering clinical trials when data are evolving.00:00 – Can SBRT change metastatic prostate cancer care? Meet Dr. Ron Chen.01:00 – Disclaimer: Views are Dr. Geo's and guests'—independent of NYU Langone.07:00 – Recurrence scenarios: prostate-only, nodal, or bone/other; why catching early matters.12:00 – Five salvage options after prostate radiation: seeds (brachytherapy), HIFU, cryo, SBRT (focal or whole-gland), or salvage prostatectomy.19:00 – Nodal relapse: treat all pelvic nodes + ADT ± abiraterone vs. SBRT to a few nodes only—how patient priorities drive the plan.26:30 – Oligometastasis: SBRT alone can control disease for many men ~2+ years on average, delaying hormones.30:00 – Fractions: why 3–5 treatments is typical and how adjacent bowel/organ anatomy sets the pace.31:00 – SBRT in 2 fractions for select primary cases looks promising; high-risk SBRT under study (NRG-GU013).37:00 – Bone mets: SBRT preferred; understanding fracture risk (tumor size, dose, shrinkage).40:00 – DEXA before ADT; spine SBRT can spare the spinal cord with modern planning.48:00 – Clavicle/hilar nodes: SBRT near lung/heart/esophagus—safe with careful dose constraints.56:00 – Why clinical trials matter for “how long on hormones?” and other open questions.57:00 – Soft-tissue mets (liver/brain): SBRT can help, often alongside systemic therapy.59:00 – Parting advice: early detection, close follow-up, and hopeful trajectory of care.___________________________________

Is androgen deprivation therapy (ADT) always necessary when prostate cancer patients undergo radiation? And if so, for how long—six months, a year, two years? In this insightful conversation, Dr. Geo sits down with Dr. Nima Aghdam, radiation oncologist at NY CyberKnife and NYU Langone, to explore the evolving role of ADT in prostate cancer treatment.Dr. Aghdam shares his expertise on advanced radiation techniques like SBRT, personalized approaches to ADT duration, and the importance of lifestyle interventions. Together, they highlight how individualized care can improve survival, minimize side effects, and help men thrive beyond diagnosis.If you or a loved one are facing decisions about radiation and hormone therapy for prostate cancer, this episode offers clarity, evidence-based guidance, and hope.Radiation vs. Surgery: Both are highly effective; choice often comes down to quality-of-life goals and patient preference.Lymph Node Positive Disease: Options include focal SBRT or comprehensive external beam therapy; treatment decisions must balance efficacy and quality of life.Lifestyle's Role: Exercise and nutrition create a “hostile microenvironment” for cancer, improving both survival and side-effect management.Radiation Innovations: From rectal spacers to fewer treatment sessions (trials reducing SBRT from five to two fractions), techniques continue to evolve.ADT Considerations:Historically prescribed for up to 24–36 months with radiation.New genomic and AI-based classifiers may allow some men to stop ADT earlier (6–12 months).Balancing survival benefits with quality of life is critical.PSA Anxiety: PSA fluctuations don't always equate to recurrence or mortality. Context and long-term monitoring matter more than isolated numbers.Finding the Right Oncologist: Beyond equipment and technology, trust and honest communication with your doctor are essential.Timestamps00:00 – Introduction: Is ADT always necessary during radiation?05:00 – Radiation vs. surgery for localized and advanced prostate cancer.10:00 – Salvage options: what happens if radiation or surgery fails?13:00 – Treating prostate cancer with lymph node involvement.17:00 – Communicating metastasis risk and long-term outcomes to patients.18:30 – Lifestyle interventions as part of prostate cancer care.21:00 – Rectal spacers and preparation for SBRT.23:30 – Advances in SBRT: reducing from five fractions to two.25:30 – Understanding fractions, dosage, and radiation delivery.32:00 – Personalizing ADT: who benefits, and for how long?36:00 – Clinical trials on ADT duration (6, 12, 18, 24+ months).39:00 – Radiation's long-lasting effects and how ADT fits in.42:00 – PSA recurrence vs. actual risk of mortality45:00 – Patient anxiety and the psychological impact of PSA testing.47:00 – Exercise and lifestyle: evidence for improved survival.49:00 – Supplements, PSA manipulation, and misinformation.51:00 – How to choose a reputable radiation oncologist.56:00 – Evolving evidence: are radiation-related risks lower today?58:00 – Parting words: seeing prostate cancer as a chance for transformation.___________________________________

Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]

Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]

Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]

Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]

Radiologist Dr. Julian Hong plains how stereotactic body radiation therapy (SBRT) is used to treat oligometastatic prostate cancer—cases where cancer has spread but only to a few limited sites. This approach targets small clusters of metastases with high-dose, image-guided radiation in five or fewer sessions. Hong reviews clinical trial evidence showing that adding focal radiation can improve outcomes, especially when all visible metastases are treated. He highlights the value of modern imaging, like PET scans, in identifying lesions and shaping personalized treatment plans. Studies suggest SBRT offers effective disease control with low toxicity and minimal impact on quality of life, making it a promising option for patients with limited metastatic spread. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40807]

What if prostate cancer surgery meant fewer incisions, faster recovery, and more precise cancer control? Today I'm joined by Dr. Michael D. Stifelman, Chair of Urology at Hackensack University Medical Center and a pioneer in robotic surgery with 4,000+ robotic procedures. We unpack how single-port robotics, real-time margin assessment, and AI are reshaping outcomes—while protecting continence and erections.Dr. Stifelman traces robotics from the early-2000s “pioneer phase” (and heavy skepticism) to today's standard of care, explaining why reproducibility, visualization, and tissue-sparing dexterity made the difference. We compare surgery vs. radiation (and focal therapies), when each shines, and why sequencing often matters—especially in higher-risk disease. He shares emerging tech like single-port prostatectomy, intra-operative margin evaluation (e.g., Histo-style scanning), quantitative surgical analytics, and even remote robotic assistance. We also talk “trifecta” outcomes, the role of genomics in Gleason 7 decision-making, and why lifestyle medicine and optimizing the tumor micro-environment go hand-in-hand with any treatment.Time-Stamped Highlights00:00 – Why fewer incisions + faster recovery are now real in prostate surgery05:40 – Work–life changes that improved health (sleep, exercise, biking)09:10 – Open vs. robotic: why reproducibility (teachability) matters11:05 – Robotics adoption curve: from early resistance to mainstream19:05 – Outcomes today: continence and erections after modern surgery20:10 – “Yes, I'm a surgeon—and here's my bias.” Radical honesty with patients22:05 – Offering the full menu: surveillance, focal (HIFU/cryotherapy), surgery, SBRT, proton25:40 – High-risk (Gleason 8–9): why surgery-first can preserve options & avoid long ADT34:00 – Dexterity & visualization: why robots spare nerves with less trauma35:10 – Real-time margin assessment during surgery to reduce positives40:00 – The “trifecta” (cancer control, continence, erections) and patient priorities42:10 – Genomics to risk-stratify Gleason 7 and guide surveillance vs. treatment45:00 – Future: nerve activation mapping & fluorescence to “light up” cancer46:10 – Single-port prostatectomy: smaller access, faster return of function (select patients)49:00 – Quantifying surgery with analytics; tele-mentoring & remote console potential52:30 – How to find Dr. Stifelman & closing advice

Check out this week's QuadCast as we highlight the limited role of axillary dissection in breast cancer, the benefits of SBRT in oligometastatic renal cell carcinoma, more data on ultra central lung cancer radiation, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

What if prostate cancer treatment weren't months of daily radiation—but five ultra-precise sessions guided in real time by MRI? Today, Dr. Michael J. Zelefsky (Professor of Radiation Oncology, NYU Grossman School of Medicine) explains how MRI-LINAC and adaptive planning are redefining accuracy, reducing side effects, and personalizing care. A pioneer behind IMRT and image-guided radiotherapy, Dr. Zelefsky breaks down SBRT vs. IMRT, protons vs. photons, HDR brachytherapy, when to add hormone therapy, and how genomics + AI are shaping what's next.In this conversation, Dr. Zelefsky charts the evolution from long-course radiation to short-course SBRT with outcomes comparable to 7–9 week regimens—thanks to precision imaging and planning. He clarifies where IMRT ends and SBRT begins, why protons haven't shown superiority over photons in prostate cancer, and where HDR brachytherapy (Ir-192) shines—especially as a boost in higher-risk disease. We dig into dose equivalence (why 5×8 Gy can match ~80–90 Gy long-course), risk-based treatment + ADT duration, and how Decipher/Artera scores can refine decisions. Most exciting: MRI-LINAC with continuous motion monitoring keeps the prostate in a virtual “bullseye,” enabling whole-gland treatment with focal boosts today—and potentially true focal therapy tomorrow as biologic imaging and AI mature.Time-Stamped Highlights00:00 – Welcome 02:00 – Why Dr. Zelefsky's work is so respected; career arc and impact04:00 – What changed: CT/MRI planning → 3D-CRT → IMRT → SBRT12:45 – IMRT vs. SBRT: definitions, session counts, who gets what19:10 – Energy sources overview: photons, protons, brachytherapy20:30 – Protons vs. photons: evidence, indications, cost, access24:00 – HDR brachytherapy (Ir-192) as a temporary “in-and-out” boost28:00 – Dose logic: why 5×8 Gy (~40 Gy) ≈ long-course 80–90 Gy29:30 – Risk groups (low/intermediate/high) and when ADT is crucial33:00 – ADT durations (6–36 months): what trials actually showed37:00 – Genomics (Decipher/Artera): resolving risk discrepancies39:00 – What MRI-LINAC adds: real-time adaptive planning43:00 – Continuous Motion Monitoring (CMM): beam stops if target moves47:00 – Treat whole gland + boost the DIL (FLAME study approach)49:00 – Toward focal therapy with better biologic imaging + AI54:00 – How to choose: values, side-effects, lifestyle, comorbidities01:01:00 – Final guidance: don't be overwhelmed—multiple good option

Check out this week's QuadCast where we highlight the pros and cons of dose de-escalated RT for resected HPV+ oropharynx cancer, another trial showing that SBRT for oligometastatic prostate cancer improves outcomes, a model for predicting brain radiation necrosis with SRS, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

In this panel discussion, UROONCO RCC associate editor Dr. Teele Kuusk talks to EAU RCC guidelines panel members Prof. Axel Bex and Assoc. Prof. Saeed Dabestani on the 2025 updates in the EAU Guidelines for renal cell carcinoma (RCC). Their conversation includes the impact of KEYNOTE-564 on adjuvant therapy, recommendations for stereotactic body radiotherapy (SBRT), surgical approaches, systemic therapies for papillary RCC, and new trial data. They also share insights into ongoing research on liquid biomarkers and perioperative treatment strategies. 

In this episode of the Dr. Geo Prostate Podcast, we welcome Dr. Jonathan Lischalk, Director of Genitourinary Cancers at MedStar Georgetown University Hospital and former Medical Director at NYU's NYCyberKnife Center. Dr. Lischalk breaks down the evolution of radiation oncology and how cutting-edge imaging and targeted SBRT (Stereotactic Body Radiation Therapy) are reshaping prostate cancer treatment.We explore how imaging advances like MRI and PSMA PET scans are enabling unprecedented precision, the future of genetic-based personalization in prostate cancer therapy, and why fewer, more focused radiation sessions might soon become the new standard. From understanding the biology of radiation dosing to upcoming trials eliminating ADT in select patients, this is a must-listen for anyone looking to stay informed on the forefront of cancer care.

Last week the Edinburgh Cancer Centre begun treating prostate cancer patients within the framework of the so-called Precision Study. Patients receive only three radiation doses, with the Raypilot System used as a complement to ensure accurate motion control during treatment, thereby minimising potential side effects. The aim is to demonstrate that three sessions work as well as five in terms of both cancer eradication and the degree of side effects. The Pace-B study*, published in 2024, showed that SBRT** with five radiation sessions is just as effective in curing cancer as traditional treatment involving 20-40 sessions. The Precision Study aims to further streamline treatment while reducing side effects and improving patient convenience. The treatments in the study are carried out using the Raypilot System, which enables real-time monitoring of organ movement. This system allows for urethra-sparing techniques and tighter radiation margins - factors that both improve targeting accuracy and reduce the risk of side effects. Prostate Cancer Treatment Aiming for Improved Quality of Life The study includes 100 patients across multiple clinics in Europe and the US and is led by Professor Duncan McLaren at the Edinburgh Cancer Centre in Scotland. His aim is to make prostate cancer treatment more comfortable for patients and improving their quality of life post-treatment. "The goal of the Precision Study is to ensure that treatment with three radiation doses does not lead to greater side effects than those observed in the Pace-B study. I am confident that we can demonstrate effective cancer treatment with less side effects," says Professor McLaren. A Collaborative Effort for Improved Healthcare The study was initiated by researchers at various clinics using the Raypilot System. "Our customers are interested in developing and improving healthcare, always with patient quality of life in focus. At the same time, healthcare providers across the Western world are striving to reduce treatment times and enhance both quality and efficiency. This study could contribute to such progress, benefiting all stakeholders - healthcare providers reduce costs while improving care, and patients gain a better quality of life," says Thomas Lindström, MD at Micropos Medical AB, the company behind the Raypilot System. The first conclusions from the Precision Study are expected within one to two years, followed by a further five years of patient follow-up before final results can be presented. See more breaking stories here.

In this episode, Dr. Shana Coplowitz highlights the numerous benefits of Stereotactic Body Radiation Therapy (SBRT) and discusses which patients are ideal candidates. If you're seeking faster treatments with fewer trips to the clinic, this episode is packed with valuable information for anyone facing a prostate cancer diagnosis.

In this episode, Dr. Geo welcomes Dr. Jonathan Haas, Director of Radiation Oncology at NYU Grossman School of Medicine in Long Island, to discuss the latest advancements in stereotactic body radiation therapy (SBRT) for prostate cancer. Dr. Haas, a pioneer in CyberKnife radiation, shares the latest research, treatment options, and what's on the horizon for prostate cancer care.Episode Highlights:✔ SBRT & CyberKnife Technology – How high-dose, highly targeted radiation is replacing traditional 9-week radiation therapy.✔ New Developments – Research is underway to reduce SBRT treatment from five sessions to just two, making therapy even more convenient.✔ Prostate Motion & Radiation Accuracy – The prostate moves during treatment—learn how advanced imaging and AI-powered tracking compensate for movement to improve precision.✔ Androgen Deprivation Therapy (ADT) & SBRT – Not all patients may need ADT. New studies explore whether men with Gleason 4+3 can avoid hormone therapy.✔ Who is a Candidate? – Understanding the differences between Gleason 6, 7, 8, and 9 patients and who may benefit most from SBRT.✔ Side Effects & Risk Factors – Discussing common side effects like bladder bleeding (2%), rectal irritation (5%), erectile dysfunction (25% over 5 years), and strictures (2%).✔ Artificial Intelligence & Radiation Therapy – The RayStation AI system is now optimizing radiation planning, increasing precision, and making treatments more effective.✔ Choosing the Right Treatment Center – Why it's crucial to seek multidisciplinary care, get second opinions, and explore clinical trials for the best possible outcome.Takeaway: The landscape of prostate cancer treatment is evolving rapidly. If you or a loved one is considering radiation therapy, ask about SBRT, AI-driven imaging, and new clinical trials to ensure you receive the most advanced and effective care.Join Dr. Geo each week for expert insights, science-backed advice, and empowering conversations designed to help you live better with age. ----------------Thank you to our partnersThe ProLon 5-Day Fasting Mimicking Diet is a plant-based meal program designed to provide fasting benefits while allowing food intake. Developed by Dr. Valter Longo, it supports cellular renewal, fat loss, and metabolic health through low-calorie, pre-packaged meals that maintain the body in a fasting state.Special Offer: Thank you for listening, you can purchase the ProLon kit for just $148 by using this link.We'd also like to thank our partner AG1 by Athletic Greens. AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the essentials in one scoop. Enjoy AG1 by Athletic Greens.----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube...

Check out this week's QuadCast as we highlight the role of staging brain MRI in metastatic breast cancer, the link between acute and late toxicity in prostate cancer treatment, the benefits of liver SBRT over TACE, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight bone SBRT guidelines, best practice in the treatment of WHO grade II meningioma, frequency of partial breast IMRT treatment, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Dr. Sue Yom, Editor in Chief, hosts guests Dr. Cristian Udovicich, a Fellow in Radiation Oncology at the University of Toronto's Sunnybrook Odette Cancer Centre, and Dr. Angela Jia, Assistant Professor and Assistant Residency Program Director at University Hospitals Cleveland Medical Center, who were the first and second authors of "Evolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging and Therapeutic Decision-Making." In addition, we review long-term SBRT results with Dr. Andrew Loblaw, Full Professor in the Department of Radiation Oncology and Institute of Health Policy, Management and Evaluation at Sunnybrook Health Science Center at the University of Toronto and supervising author of "Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials," and Dr. Constantinos Zamboglou, Deputy Medical Director at the German Oncology Center in Limassol, Cyprus and first author of an accompanying editorial, "Stereotactic Body Radiotherapy for Prostate Cancer is Getting Mature: 10-Year Outcomes From Three Prospective Trials."

Check out this week's QuadCast as we highlight spinal cord constraints for spine SBRT, published results of RTOG 1112 where liver SBRT shines, the role of prophylactic nodal RT in prostate SBRT, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

Check out this week's QuadCast where we highlight the benefits of considering short course RT instead of years of endocrine therapy for low risk breast cancer patients, the superiority of SBRT over ablation for recurrent HCC, and much more! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

ABOUT THIS EPISODEWhat is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing.TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY FOR NEUROENDOCRINE CANCERS:1. What is radiation oncology? How does it work? How is it different from other types of radiation?2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective?Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used?Is there a number or size limit of the tumor(s)?4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it?If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT?If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated?How common is increased pain after treatment to the bone? What causes that?5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?)Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans?How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they?Is there a risk with fertility?What other risks are there?6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give?9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor?  How do you know if the treatment “worked”?Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment?For more information, visit LACNETS.org.

Check out this week's QuadCast where we highlight the reduced toxicity of reduced-margin MRI-guided prostate SBRT, the response rate of double hit lymphoma to radiation, the inappropriate radiation services denial rate of Medicare Advantage plans, and more! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

In this edition of the On Target podcast, Dr Akila Viswanathan speaks with Dr Kristin Redmond about treating brain and spinal tumors and her research on stereotactic body radiation therapy (SBRT). Dr Redmond discusses some ongoing clinical trials using SBRT, a highly precise form of radiation therapy used to treat tumors in while minimizing damage to surrounding areas, that are exploring optimal doses and treatment techniques to improve patient outcomes. They also highlight the benefits of collaboration in multidisciplinary care at Johns Hopkins, where experts from radiation oncology, medical oncology, surgery, radiology and other fields work together to provide the best possible care for patients with complex cases, including rare tumors. Dr Redmond also touches on the innovative use of circulating tumor DNA to detect tumor recurrence early and her research on the neuropsychological effects of radiation on the brain.

Check out this week's QuadCast where we highlight the important results of the PACE-B trial for prostate SBRT, the utility of frozen section analysis of SLN bx in oral cavity cancer, dose de-escalation for gastric MALT lymphoma, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Workup and management of Kidney Cancer in Radiation Oncology featuring guest Dr Riche Mohan

Check out this week's Quadcast as we highlight the first randomized trial of SBRT vs. Surgery for prostate cancer, the impact of pembrolizumab on survival in triple negative breast cancer, and the improved survival in limited stage small cell lung cancer with the addition of Durvalumab. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Kidney Cancer & SBRT in the Management of RCC AUA Urology Core Curriculum: auau.auanet.org/core Host: Jay D. Raman, MD, FACS, FRCS(Glasg) Guest: Daniel Shapiro, MD Outline: Segment 1: History of radiation therapy in renal cell carcinoma Segment 2: Radiation use in the setting of primary kidney tumors Segment 3: Radiation use for locally advanced tumors including tumor thrombi Segment 4: Radiation therapy for metastatic disease Segment 5: Limitations of radiation therapy and selecting patients for radiation therapy

Check out this week's QuadCast as we highlight SBRT for oligometastatic pancreatic cancer, preoperative APBI, the role of post-lumpectomy mammograms prior to RT, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Editor in Chief Sue Yom hosts a discussion of An Economic Analysis of SC.24: A Randomized Study of SBRT Compared with Conventional Palliative RT for Spinal Metastases. Guests are first and second author Dr. Marc Kerba, clinical associate professor in the Department of Oncology at the University of Calgary and radiation oncologist at the Tom Baker Cancer Centre, and Dr. Richard De Abreu Lourenco, Professor with the Centre for Health Economics Research and Evaluation at the University of Technology Sydney.

Check out this week's Quadcast where we highlight the role of FMISO PET to identify tumor hypoxia for attempts at dose de-escalation in HPV mediated HNSCC, ASTRO's new guidelines on bone metastasis treatment, SBRT for mediastinal LNs, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Editor-in-Chief, Robert Amdur, MD, discusses using SBRT dose schedules to re-irradiate large volume recurrences of locally advanced Non-Small Cell Lung Cancer that has progressed following high-dose radiotherapy with conventional fractionation. The discussion is based on a paper published in the May 2024 issue of PRO titled "Thoracic Reirradiation with Stereotactic Body Radiation Therapy (SBRT) for Recurrent Advanced Non-Small Cell Lung Cancer (NSCLC)” (2024, Issue 3, May/June, PMID 38387781).

In this episode of the Oncology Brothers podcast, join Drs. Rahul and Rohit Gosain as they delve into the world of localized treatment options for gastrointestinal malignancies. They are joined by experts in the field, Drs. Nina Sanford, Jeffrey Ryckman, and Harris Chengazi, who provide insights into radiation oncology and interventional radiology modalities for treating liver cancer. The discussion covers the basics of radiation oncology terminology, including SRS, SBRT, and proton therapy, and how these modalities have evolved over the last decade. The experts also discuss the various tools available in the interventional radiology toolkit, such as ablation techniques, chemoembolization, and radioembolization. Listeners gain valuable insights into the considerations for referring patients with liver-confined hepatocellular carcinoma to radiation oncologists or interventional radiologists, depending on the size of the tumor and underlying liver function. The experts emphasize the importance of a multidisciplinary approach in cancer care to ensure the best treatment outcomes for patients. Tune in to learn about the side effects of SBRT, the nuances of combining different treatment modalities, and the significance of collaboration among oncology specialists. This episode highlights the importance of understanding and appreciating the diverse treatment options available for cancer patients. Don't miss out on this informative discussion on localized treatment options for gastrointestinal malignancies with the Oncology Brothers podcast.   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Check out this week's Quadcast as we highlight SBRT for oligoprogressive prostate cancer, salvage SRS for high risk meningiomas, changes in breast cancer screening recommendations, and more! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

At the end of last year, Dr. Jason Beckta published a docu-podcast about clinical supervision of radiotherapy services (parts one, two, and three). The series covers supervision terms, legal precedent, and dispels the misinformation shared by conflicted parties.  In this episode, The Accelerators (Drs. Matt Spraker and Simul Parikh) join up with Jason to interview the famous Dr. Todd Scarbrough, the radiation oncologist at the center of supervision lore.Todd shares his story and we discuss many aspects of supervision policy. Here are some links to things discussed in the show:TAP Episode with Simul, Jason, and Todd from ACRO 2022Jarvis et al., Initial Clinical Experience of Cherenkov Imaging in External Beam Radiation Therapy Identifies Opportunities to Improve Treatment DeliveryPrice et al., Washington University in St. Louis experience with remote SBRT coverage and adaptive radiotherapy coverageThe Accelerators Podcast is a production of Photon Media, a division of the Cold Light Legacy Company.If you'd like to support our efforts, please visit the Cold Light Legacy Company to learn more.

Editor-in-Chief, Robert Amdur, MD, reviews the evidence for treating Low-Intermediate Risk prostate cancer with Ultra Hypofractionated SBRT. This discussion was stimulated by a paper published in the November/December 2023 issue of PRO titled “Long-Term Outcomes of a Prospective Study on Highly Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer for 3 Weeks” with PMID 37414247. However, the majority of the podcast will focus on data supporting 5 Fraction SBRT, including the most recent report from the PACE-B trial (Abstract only from the 2023 ASTRO annual Meeting).

Editor-in-Chief Sue Yom hosts Dr. Karin Lindberg, a Clinical Oncologist at the Karolinska Institute in Sweden and the supervising author of a new paper this month, "Expanded HILUS trial - a pooled analysis of risk factors for toxicity from SBRT of central and ultra-central lung tumors," and Dr. David Palma, a Radiation Oncologist at the London Health Sciences Centre who co-authored the accompanying editorial, "Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultra-Central Thoracic Tumors?" Dr. Palma also describes the design and findings of the new clinical trial SUNSET, which he presented in the Multidisciplinary Thoracic Cancer Symposium plenary session simultaneously with this podcast release.

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Esseim Sharma, MD, of University Hospitals Cleveland, and Paul C Zei, MD, PhD, FHRS, of Brigham and Women's Hospital to discuss One-Year Outcomes Following Stereotactic Body Radiotherapy for Refractory Ventricular Tachycardia. Cardiac stereotactic body radiotherapy (SBRT) has emerged as a promising noninvasive treatment for refractory ventricular tachycardia (VT). The objective is to describe the safety and effectiveness of SBRT for VT in refractory to extensive ablation. For a select group of high-risk patients with VT refractory to standard therapy, SBRT is associated with a reduction of in VT and appropriate ICD therapies.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(23)02782-0/fulltext    Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic   Contributor Disclosure(s): E. Sharma: No relevant financial relationships with ineligible companies to disclose.  P. Zei: Honoraria/Speaking/Consulting Fee: Varian Medical Systems, Biosense Webster, Inc., Abbott; Research (Contracted Grants for PIs Named Investigators Only): Biosense Webster, Inc.; Stocks (Publicly Traded): Affera, Inc.

Episode two of the Radiation Therapy podcast series discusses treatment of Oligometastatic disease, re-irradiation and role of palliative radiation, utilization of SBRT, introduction to proton therapy and mitigation of radiation-associated toxicities. Host: Mian M. Shahzad, MD, PhD (Gynecologic Oncologist; H. Lee Moffitt Cancer Center)Guest Speaker: Michael Montejo, MD (Radiation oncologist; H. Lee Moffitt Cancer Center) Sound engineered and produced by Tanya Colomb on behalf of the Society of Gynecologic Oncology.

This week on BackTable Urology, Dr. Aditya Bagrodia (UCSD), medical oncologist Dr. Rana McKay (UCSD) and radiation oncologist Dr. Shankar Siva (University of Melbourne) discuss the growing role of radiation therapy in kidney cancer treatment. --- SHOW NOTES Shankar first explains the original historical studies that provided evidence of the limited efficacy of low dose conventional radiation therapy (RT) in treating kidney cancer. However, he and Rana discuss how stereotactic body radiation therapy (SBRT), a newer technology which delivers a higher dose per fraction more accurately, has shown better outcomes in clinical trials than conventional RT. They also explain the associated risks with SBRT and how neoadjuvant therapies can be combined with radiation. They also consider the use of SBRT in bulky tumors and those with IVC thrombus. All three doctors agree that radiation therapy needs to be incorporated into a multimodal approach to kidney cancer. They also discuss the potential of radiation therapy in the cytoreductive setting and its role in delaying systemic therapy in patients with oligometastases. Finally, they explore the possibility of using PET imaging to detect oligometastatic disease. Although prostate-specific membrane antigen positron emission tomography (PSMA PET/CT) imaging is mostly used to stage prostate cancer, other solid tumors like renal cell carcinoma (RCC) may also express PSMA. For this reason, they agree that a next generation PSMA PET/CT equivalent for RCC could be revolutionary. Lastly, they predict what the future of RCC could hold by examining newer therapies, such as radioligand therapy and cyberknife. --- RESOURCES Kidney Cancer Association: 2023 International Kidney Cancer Symposium (Nov. 9-11) https://www.kidneycancer.org/ikcs/2023-ikcs-north-america/ Decipher by Veracyte https://decipherbio.com/ WellPrept https://wellprept.com/

Check out this week's QuadCast as we highlight some of the most important data from ASTRO 2023, including SBRT for Renal Cell Carcinoma, SRS for small cell, RT instead of transplant for relapsed Hodgkin lymphoma, and more!

On this episode of Oncology Unscripted, patient advocates Julie Johnson and Katie Coleman and radiation oncologist Dr. Matt Spraker continue The Insider's Guide to Radiation Therapy! This four episode series will cover radiation 101, stereotactic body radiation therapy (SBRT), and proton therapy!In this episode, we discuss SBRT, alternatively called stereotactic ablative body radiotherapy (SABR). We also discuss a related treatment, stereotactic radiosurgery (SRS).Here are some links to things we discussed during the show:Rare Cancer Research FoundationPattern.orgCount Me InJAMA Oncology SBRT/SABR patient pageCyberKnife information from the manufacturer (Accuray)GammaKnife information from the manufacturer (Eleckta)The patient-led Remove the Mask CampaignHere are some clinical and scientific publications mentioned during this show:Original Timmerman study of SBRT for early stage lung cancerDiscovery of the SBRT "No Fly Zone" in the chestInternational Radiosurgery Consortium of the Kidney (IROCK) meta-analysis of SBRT for primary kidney cancer (renal cell carcinoma).Here are some resources that may be of interest, but were not discussed in this episode:An excellent video on Stereotactic Radiosurgery (SRS) versus Whole Brain Radiotherapy (WBRT) for brain metastases from our friends at PRIMRRTOG 1112 Trial: Benefit of adding SBRT to Sorafenib in locally advanced liver cancer (hepatocellular carcinoma). (conference abstract only)TRENDY Trial: Suggests that SBRT is superior to trans-arterial chemoembolization (TACE) for early liver cancer (haptocellular carcinoma).MD Anderson Cancer Center Phase II Trial: Suggests that SBRT may be used to defer systemic therapy in patients with oligometastatic kidney cancer (renal cell carcinoma) Oncology Unscripted is a Photon Media production. Intro and Outro music by Emmy-award winning artist Lucas Cantor Santiago.Additional content from Katie Coleman can be found at her website, https://www.katiekickscancer.com/. This show and our opinions are meant for general informational purposes and are not medical advice. We encourage you to reach out to your doctors to discuss your individual case. 

On this episode of Oncology Unscripted, patient advocates Julie Johnson and Katie Coleman and radiation oncologist Dr. Matt Spraker continue The Insider's Guide to Radiation Therapy! This four episode series will cover radiation 101, stereotactic body radiation therapy (SBRT), and proton therapy!In this episode, we complete radiation 101, covering 2 more important points to understand radiotherapy:1. How are radiation plans created and delivered, and how has this improved over decades?2. Who are the workers in the Radiation Oncology department and what is the workflow that patients experience when getting treatment?Here are some other things we discussed during the show:Explanation of Intensity Modulated Radiation Therapy (IMRT), UCLA HealthMultileaf Collimator (MLC) video, Phoenix CyberknifePercentage depth dose curveAn "old" radiotherapy block, Vishal Majithia on FlikrOncology Unscripted is a Photon Media production. Intro and Outro music by Emmy-award winning artist Lucas Cantor Santiago.Additional content from Katie Coleman can be found at her website, https://www.katiekickscancer.com/. This show and our opinions are meant for general informational purposes and are not medical advice. We encourage you to reach out to your doctors to discuss your individual case. 

On this episode of Oncology Unscripted, patient advocates Julie Johnson and Katie Coleman and radiation oncologist Dr. Matt Spraker kick of The Insider's Guide to Radiation Therapy! This four episode series will cover radiation 101, stereotactic body radiation therapy (SBRT), and proton therapy!  Radiation 101 covers the basics you need to know in order to understand how oncologists think about and use radiotherapy to kill cancer. In this episode we discuss two important points:What is radiation and how does it kill cancer (and affect other tissues)?How is radiation therapy used in medicine?Here are some links to things mentioned in the show:Matt on "Ask Me Anything" - Radiation Therapy for Sarcoma (YouTube)Electromagnetic energy figureA nice written history of radiotherapy - cancer.orgSpoon of Sugar Podcast - a very nice, detailed overview of radiation therapyHow Do X-Rays Work? - HowStuffWorks.comOncology Unscripted is a Photon Media production. Intro and Outro music by Emmy-award winning artist Lucas Cantor Santiago.Additional content from Katie Coleman can be found at her website, https://www.katiekickscancer.com/. This show and our opinions are meant for general informational purposes and are not medical advice. We encourage you to reach out to your doctors to discuss your individual case.